Exelixis, Inc. (EXEL)
69.00
-0.84
(-1.20%)
USD |
NASDAQ |
Nov 13, 10:06
Exelixis EPS Diluted (Quarterly) : 0.8528 for Sept. 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.8528 |
| June 30, 2026 | 0.8166 |
| March 31, 2026 | 0.7873 |
| December 31, 2025 | 0.8849 |
| September 30, 2025 | 0.695 |
| June 30, 2025 | 0.65 |
| March 31, 2025 | 0.5539 |
| December 31, 2024 | 0.4764 |
| September 30, 2024 | 0.4047 |
| June 30, 2024 | 0.7692 |
| March 31, 2024 | 0.1221 |
| December 31, 2023 | 0.2732 |
| September 30, 2023 | 0.0033 |
| June 30, 2023 | 0.248 |
| March 31, 2023 | 0.1227 |
| December 31, 2022 | -0.0933 |
| September 30, 2022 | 0.2252 |
| June 30, 2022 | 0.2175 |
| March 31, 2022 | 0.2121 |
| December 31, 2021 | 0.2945 |
| September 30, 2021 | 0.1186 |
| June 30, 2021 | 0.2976 |
| March 31, 2021 | 0.005 |
| December 31, 2020 | 0.0888 |
| September 30, 2020 | -0.1036 |
| Date | Value |
|---|---|
| June 30, 2020 | 0.21 |
| March 31, 2020 | 0.1539 |
| December 31, 2019 | 0.2182 |
| September 30, 2019 | 0.3089 |
| June 30, 2019 | 0.251 |
| March 31, 2019 | 0.2408 |
| December 31, 2018 | 1.152 |
| September 30, 2018 | 0.4054 |
| June 30, 2018 | 0.2802 |
| March 31, 2018 | 0.3693 |
| December 31, 2017 | 0.12 |
| September 30, 2017 | 0.26 |
| June 30, 2017 | 0.06 |
| March 31, 2017 | 0.054 |
| December 31, 2016 | 0.12 |
| September 30, 2016 | -0.04 |
| June 30, 2016 | -0.15 |
| March 31, 2016 | -0.26 |
| December 31, 2015 | -0.18 |
| September 30, 2015 | -0.22 |
| June 30, 2015 | -0.22 |
| March 31, 2015 | -0.18 |
| December 31, 2014 | -0.30 |
| September 30, 2014 | -0.32 |
| June 30, 2014 | -0.38 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| BioMarin Pharmaceutical, Inc. | -0.6345 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Cytokinetics, Inc. | -1.367 |
| Gilead Sciences, Inc. | 1.942 |
| Ionis Pharmaceuticals, Inc. | -0.6617 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 218.10M |
| Revenue (Quarterly) | 658.70M |
| Total Expenses (Quarterly) | 440.60M |
| Enterprise Value | 16.36B |
| Gross Profit Margin (Quarterly) | 96.02% |
| Profit Margin (Quarterly) | 33.11% |
| Earnings Yield | 4.84% |
| Operating Earnings Yield | 5.50% |
| Normalized Earnings Yield | 4.845 |